PA
ALLO icon

Profund Advisors’s Allogene Therapeutics ALLO Stock Holding History

Profund Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$353K Buy
169,698
+43,842
+35% +$96.3K 0.01% 708
2026
Q1 		$307K Buy
+125,856
New +$252K 0.01% 735
2025
Q1 		– Sell
-70,325
Closed -$150K – 994
2024
Q4 		$150K Buy
70,325
+7,691
+12% +$19K 0.01% 1044
2024
Q3 		$175K Sell
62,634
-13,526
-18% -$36.1K 0.01% 1070
2024
Q2 		$177K Sell
76,160
-44,899
-37% -$132K 0.01% 1003
2024
Q1 		$541K Buy
+121,059
New +$505K 0.02% 546
2023
Q4 		– Sell
-130,639
Closed -$414K – 1131
2023
Q3 		$414K Sell
130,639
-6,593
-5% -$28.9K 0.02% 520
2023
Q2 		$682K Buy
137,232
+12,621
+10% +$68.3K 0.04% 416
2023
Q1 		$616K Buy
+124,611
New +$799K 0.04% 443
2022
Q3 		– Sell
-10,229
Closed -$117K – 925
2022
Q2 		$117K Sell
10,229
-1,014
-9% -$9K 0.01% 962
2022
Q1 		$102K Sell
11,243
-1,249
-10% -$13K ﹤0.01% 1321
2021
Q4 		$186K Sell
12,492
-1,488
-11% -$26.3K 0.01% 1295
2021
Q3 		$359K Buy
13,980
+631
+5% +$15K 0.01% 818
2021
Q2 		$348K Buy
13,349
+55
+0.4% +$1.57K 0.01% 932
2021
Q1 		$469K Sell
13,294
-1,292
-9% -$43.6K 0.02% 635
2020
Q4 		$368K Buy
14,586
+1,454
+11% +$47.4K 0.02% 704
2020
Q3 		$495K Sell
13,132
-1,946
-13% -$73.4K 0.03% 458
2020
Q2 		$646K Buy
15,078
+4,867
+48% +$176K 0.04% 353
2020
Q1 		$199K Sell
10,211
-4,089
-29% -$97.4K 0.01% 653
2019
Q4 		$372K Buy
14,300
+1,712
+14% +$47.2K 0.02% 780
2019
Q3 		$343K Buy
+12,588
New +$359K 0.02% 836

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Profund Advisors's ALLO Position: Q2 2026 in Review

Profund Advisors increased its Allogene Therapeutics (ALLO) stake by 35% in Q2 2026, buying an estimated $96.3K and bringing the position to 169,698 shares worth $353K. The position accounts for 0.01% of the portfolio, ranked #708.

Profund Advisors first reported a position in ALLO in Q3 2019 and has held it in 21 quarters since. The position peaked at $682K in Q2 2023. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Profund Advisors held 169,698 shares of Allogene Therapeutics worth $353K as of Q2 2026.
  • Profund Advisors bought 43,842 Allogene Therapeutics shares in Q2 2026, an estimated $96.3K.
  • Allogene Therapeutics made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #708 holding.
  • Profund Advisors first reported a position in Allogene Therapeutics in Q3 2019 and has held it in 21 quarters since.
  • Profund Advisors's Allogene Therapeutics position peaked at $682K in Q2 2023.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.